An observational study in NSCLC, sponsored by Yuhan Corporation. Active, not recruiting at 39 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by Yuhan Corporation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR mutation to collect and analyze the patient's clinical features, diagnosis, and treatment results.
The Korean EGFR Registry is a prospective multicenter observational cohort study designed to enroll all stage EGFR-mutated non-small cell lung cancer (NSCLC) patients. However, due to the extended follow-up period required to confirm clinical outcomes, a retrospective cohort has been included. This retrospective cohort comprises patients with recurrent or metastatic NSCLC who began taking EGFR TKI after January 2021. The recruitment phase was planned to span 36 months, commencing in May 2022, with scheduled follow-up activities continuing until December 2026. The target enrollment for this study is set at 2,000 patients, with competitive enrollment to be carried out across 40 university hospitals in Korea.
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with non-small cell lung cancer of any stage with an EGFR mutation newly diagnosed after the date of IRB approval, or patients who started EGFR-targeted therapy for the first time after 2021-01-01 with metastatic or recurrent EGFR mutation non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical characteristics of NSCLC patients with EGFR mutation
Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation
Time frame: 12months, 18months, 24months, 36months
Clinical outcome of NSCLS patients with EGFR mutation
Analysis of clinical characteristics and clinical outcomes in NSCLC patients with EGFR mutation
Time frame: 12months, 18months, 24months, 36months
PFS
PFS underwent palliative therapy according to stages in NSCLC patients with EGFR mutation
Time frame: 12months, 18months, 24months, 36months
DFS
DFS in patients underwent definitive therapy according to stages in NSCLC patients with EGFR mutation
Time frame: 12months, 18months, 24months, 36months
Diagnosis Test Method
Frequency of diagnostic test methods according various clinical samples
Time frame: up to 36months
Diagnosis Test Method
Proportion of diagnostic test methods according various clinical samples
Time frame: up to 36months
OS(Overall survival)
Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation
Time frame: up to 36months
ORR(overall response rate)
Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation
Time frame: up to 36months
DoR (duration of response)
Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation
Time frame: up to 36months
DCR (disease control rate)
Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation
Time frame: up to 36months
TTF (time to treatment failure)
Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation
Time frame: up to 36months
TTNF (time to next treatment)
Exploration of clinical outcomes according to treatment modality in NSCLC patients with EGFR mutation
Time frame: up to 36months
Analysis of metastatic sites and treatment patterns (especially brain and bone metastasis)
Exploration of clinical characteristics and metastatic patterns in NSCLC patients with EGFR mutation
Time frame: up to 36months
Adverse event profiles
Adverse event profiles after lazertinib administration
Time frame: up to 36months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.